FDA Investigator Nina Yang

Nina Yang has conducted inspections on 76 sites in 2 countries as of 24 Aug 2021. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
76
Last Inspection Date:
24 Aug 2021
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, Romania
FDA Investigators that have inspected at least one site in common with Nina Yang:
Addam S Reynolds, Adetutu M Gidado, Alberto A Viciedo, Allen Lou, Amy L Singer, Anastasia I Offordile, Ankur C Patel, Anna R Kwilas, Annemarie Bodnar, Annet R Rajan, Anthony C Warchut, Anthony J Donato, Arindam Dasgupta, PhD, Barbara J Maulfair, Barbara Jwilimczyk Macri, Bei Yu, Brooke K Higgins, Byungja E Marciante, Cary Greene, Charles J Chacko, Cheryl A Grandinetti, Christina N Maurino, Christina P Burkhart, Christine M Whitby, CSO, Christopher Janik, Chunsheng Cai, PhD, Craig T Rybus, Cynthia F Kleppinger, MD, Daniel J Grabicki, Darin S Wiegers, Dawn L Wydner, Deborah B Nixon, Dena M Elimam, Denise M Visco, Investigator, Devon Jenkins, Dhaval H Patel, Diane C Thibodeau, Dien N Nguyen, Dolores Harper, Dorothy J Denes, Douglas C Kovacs, Edmund F Mrak, Jr, Edward J Janik, Emest F Bizjak, Emily A Walters, Emmanuel Jramos Maldonado, Eric Rothschild, Erin D Mccaffery, Frederick F Razzaghi, Gabrielle J Swain, George Pyramides, Guerlain Ulysse, Haley H Seymour, Hang N Guo, Helen B Ricalde, Hitesh R Patel, Iram R Hassan, PhD, Jacqueline A O'shaughnessy, PhD, James R Birkenstamm, Jason M Sluzynski, Jean M Kelahan, Jean M Mulinde, MD, Jessica M Monteiro, Jo Annc Declement, Joan A Loreng, Jogy George, Jonah S Ufferfilge, Jonee J Mearns, Jose M Cayuela, Joseph L Despins, PhD, Joy Rkozlowski Klena, Judith A Jones, Justine Tomasso, Kara A Scheibner, PhD, Karen E D'orazio, Karen F Tomaziefski, Kassa Ayalew, MD, Kelli F Dobilas, Kelly N Kerr, Kent A Conforti, Kerry A Kurdilla, Kimberly L Schultz, Kinh Q Mac, Kristen E Rescigno, Kristy A Zielny, Krystal O Ogunremi, Laishan L Lam, Lata C Mathew, PhD, Lauren Iacono Connors, PhD, Lawrence Harmon, Jr, Lawrence R Johnson, Liatte Kreuger, PharmD, Linda Thai, Lisa Harlan, Lisa Mathew, Loretta Nemchik, Marcelo O Mangalindan, Jr, Marea K Harmon, Margaret M Sands, Maria Estrella, Marjorie D Schultz, Mark R Mcclain, Martin K Yau, PhD, Matthew A Spataro, Matthew C Watson, Maya M Davis, Mayar M Mussa, Melissa B Libby, Melissa T Roy, Meredith L Sheridan, Michael Serrano, Michelle A Marsh, Michelle M Noe Varga, Mohsen Rajabi Abhari, FDA, Namita Kothary, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Nealie C Newberger, Nerizza B Dalena, Nerizza B Guerin, Nicholas A Violand, Nimmy Mathews, Paul L Bellamy, Peter R Lenahan, Rapti D Madurawe, Raymond L Cheung, Regina T Brown, Remache, Robert Jennings, Rodney T Allnutt, Russell J Glapion, Ruth A Williams, Sherri J Liu, Shirley H Isbill, Shirley S Wen, Sinai I Davis, Stephanie Mangigian, MS/OSH, RN, Stephanie T Durso, Stephen J Mottola, Stephen R Souza, Susan M Halsted, Syeda N Mahazabin, Tonia F Bernard, Tyanna N Hadley, Unnee Ranjan, Valerie C Reed, Victoria M Daddeo, Xiaohan Cai, PhD, Yvesna C Blaise, Zakaria I Ganiyu

Nina Yang's Documents

Publish Date Document Type Title
January, 2017 FDA 483 Novartis Pharmaceuticals Corporation - Form 483, 2017-01-24
October, 2018 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2018-10-05
February, 2020 EIR Dr. Reddy's Laboratories, Inc. - EIR, 2020-02-07
January, 2021 EIR Merck & Company - EIR, 2021-01-20
November, 2019 EIR Syneos Health Clinical, Inc. - EIR, 2019-11-08
July, 2016 EIR Kourosh Asgarian, MD - EIR, 2016-07-14
January, 2017 EIR Novartis Pharmaceuticals Corporation - EIR, 2017-01-24
July, 2019 FDA 483 Novartis Pharmaceuticals Corporation - Form 483, 2019-07-02
April, 2019 EIR Appco Pharma LLC - EIR, 2019-04-15
May, 2019 FDA 483 SK Life Science Inc. - Form 483, 2019-05-22
August, 2021 FDA 483 Insmed, Inc. - Form 483, 2021-08-03
June, 2020 EIR CELGENE CORPORATION - EIR, 2020-06-03
January, 2018 FDA 483 Steven David, M.D. - Form 483, 2018-01-08
October, 2017 FDA 483 Merck Sharp & Dohme LLC - Form 483, 2017-10-30
September, 2017 EIR David R. Hassman, DO - EIR, 2017-09-27
November, 2017 FDA 483 Kyowa Kirin Pharmaceutical Development, Inc. - Form 483, 2017-11-29
August, 2016 FDA 483 Sanofi US - Form 483, 2016-08-03
April, 2021 FDA 483 Robert S. Falcone, M.D. - Form 483, 2021-04-05
February, 2018 FDA 483 Eisai, Inc. - Form 483, 2018-02-16
August, 2016 FDA 483 Merck Sharp & Dohme LLC - Form 483, 2016-08-26
December, 2020 EIR ADC Therapeutics, SA - EIR, 2020-12-22
April, 2019 FDA 483 Appco Pharma LLC - Form 483, 2019-05-03
January, 2021 FDA 483 Merck & Company - Form 483, 2021-01-20
September, 2017 EIR Novartis Pharmaceuticals Corporation - EIR, 2017-09-07
July, 2016 FDA 483 Kourosh Asgarian, MD - Form 483, 2016-07-14
May, 2018 FDA 483 Allergan, PLC. - Form 483, 2018-05-16
July, 2016 FDA 483 Response Kourosh Asgarian, MD - Form 483R, 2016-07-24

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more